Cape Town | A portfolio of clinical research programmes are set to get underway on South African soil with the potential to enhance our scientific understanding of non-communicable diseases (NCDs); including the treatment of cancer, heart disease, diabetes and kidney disease.
Heeding predictions from the World Health Organisation that NCDs will be the most common cause of death in Africa by 2030, a novel public-private collaboration between the UK and South Africa has responded by investing over 80M ZAR into South Africa’s medical research capabilities. This initiative between the South African Medical Research Council (SAMRC), GlaxoSmithKline’s (GSK) Africa NCD Open Lab and the Newton Fund via the UK Medical Research Council, will also offer skills transfer to clinicians and academics who receive funding through the network.
Dr Mark Palmer, Director of International Strategy at the UK’s Medical Research Council said: “According to the WHO, NCDs kill 38 million people each year with almost three quarters of these deaths - 28 million - occurring in low- and middle-income countries. It is clear that addressing the burden of NCDs around the world demands a global response. These exciting collaborations between GSK and excellent academic scientists from the UK and South Africa represent part of the MRC’s international effort to pool expertise and resources and deliver research that will make a real difference in tackling these diseases.”
Dr Mike Strange, head of GSK’s Africa NCD Open Lab, said “GSK is excited to collaborate, through the Africa NCD Open Lab, on this portfolio of research projects that have the potential to enhance the understanding of NCDs in Africa, and which could ultimately improve the treatment of these diseases. At GSK, we believe that collaboration is key to tackling some of the world’s biggest health problems and the initiative announced today is a fantastic endorsement of this open approach.”
“Our research at the SAMRC revealed that non-communicable diseases have now become the leading group of causes resulting in death in South Africa accounting for almost 40% of total deaths and 1 in 3 deaths before the age of 60 years” says Professor Glenda Gray, President & CEO of the SAMRC. “Our ammunition in this battle is our medical research”, Gray concluded.
Two of the principal investigators that successfully competed for funding through this initiative are on a path to contribute new insights into NCDs through their respective research into cardiovascular disease and oesophageal cancer.
“Oesophageal cancer is the eighth most common cancer in the world, comprising adenocarcinoma that occurs mainly in industrialised countries and squamous cell carcinoma that occurs mainly in developing countries. Squamous cell oesophageal carcinoma, in the Eastern Cape of South Africa, is the most common cancer in males and the second most common cancer in females”, says Professor Iqbal Parker, founding Director of the Cape Town Component of the International Centre for Genetic Engineering and Biotechnology and currently Research Professor at the University of Cape Town.
“The average age at diagnosis is 56 years, with the majority of patients presenting at an advanced stage (Stage III), when they experience great difficulty in swallowing solids and liquids. The five-year survival rate is less than 10% and has remained unchanged over the last three decades”, Parker elaborates. Professor Parker’s ZAR 9.95 million study will investigate the genetic and environmental risk factors in the Kenyan and South African populations with the objective of identifying new treatment modalities involving repurposing of existing drugs and development of new drug targets.
The increasing incidence of Cardiovascular disease and hypertension in Africa is believed to result from a combination of factors such as rapid urbanization, abnormal sodium handling, elevated vascular resistance and arterial stiffness. The lack of awareness, frequent underdiagnoses and ineffective treatment of hypertension in general but especially in Africans, result in severe complications, such as stroke, heart and kidney disease.
“In our study we aim to identify early markers or predictors for the development of cardiovascular diseases in black South Africans”, says Principal Investigator, Professor Alta Schutte, Director of the MRC Unit for Hypertension and Cardiovascular Disease at North-West University. “Only by identifying such markers as potential screening indicators, predictors or targets for intervention, will we be able to implement successful prevention programmes in Africans at younger ages”, Schutte concluded. An estimated ZAR 9 million has been invested in Schutte’s study.
All research supported through this initiative is conducted with the full engagement of African scientific leaders and clinical research communities, and the results will be shared with the wider community to help achieve the World Health Assembly goal of a 25% reduction in avoidable mortality from NCD’s by 2025.
- GSK’s Africa NCD Open Lab was established in 2014 with a commitment to working in partnership with major funders, academic groups and governments to share GSK’s expertise and resources in conducting NCD research in Africa.
- The Newton Fund builds scientific and innovation partnerships with 16 partner countries to support their economic development and social welfare, and to develop their research and innovation capacity for long-term sustainable growth. It has a total UK Government investment of £735 million up until 2021, with matched resources from the partner countries. The UK and South Africa Newton Fund is managed by the UK Department for Business, Energy and Industrial Strategy (BEIS) and South Africa’s Department for Science and Technology, and delivered through UK and South African Delivery Partners, which include the Research Councils. For further information visit the Newton Fund website and follow via Twitter: @Newton Fund
- The Grants, Innovation and Product Development (GIPD) unit manages external grant funding and innovation activities within the South African Medical Research Council (SAMRC). These activities are managed through a number of business units, platforms and programmes. The Strategic Health Innovation Partnerships (SHIP) unit, which forms part of GIPD, manages funding for translational research and product development in key health priority focus areas, including NCDs. Additional information on GIPD & SHIP can be accessed at: www.samrc.ac.za
Zara Roman | Newton Fund Country Manager, South Africa |
Tel: +27 (0) 21 405 2414 |
Head of Corporate Communications
Tel: + 27 21 938 0274